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Notch signaling is a well-known key player in the communication between adjacent cells 
during organ development, when it controls several processes involved in cell differ-
entiation. Notch-mediated communication may occur through the interaction of Notch 
receptors with ligands on adjacent cells or by a paracrine/endocrine fashion, through 
soluble molecules that can mediate the communication between cells at distant sites. 
Dysregulation of Notch pathway causes a number of disorders, including cancer. Notch 
hyperactivation may be caused by mutations of Notch-related genes, dysregulated 
upstream pathways, or microenvironment signals. Cancer cells may exploit this aberrant 
signaling to “educate” the surrounding microenvironment cells toward a pro-tumoral 
behavior. This may occur because of key cytokines secreted by tumor cells or it may 
involve the microenvironment through the activation of Notch signaling in stromal cells, 
an event mediated by a direct cell-to-cell contact and resulting in the increased secretion 
of several pro-tumorigenic cytokines. Up to now, review articles were mainly focused on 
Notch contribution in a specific tumor context or immune cell populations. Here, we pro-
vide a comprehensive overview on the outcomes of Notch-mediated pathological inter-
actions in different tumor settings and on the molecular and cellular mediators involved 
in this process. We describe how Notch dysregulation in cancer may alter the cytokine 
network and its outcomes on tumor progression and antitumor immune response.
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iNTRODUCTiON
The critical events in tumor development and progression include heterotypic interactions between 
neoplastic cells and normal components of the tumor niche. This crosstalk causes the activation 
of several signaling pathways that, in turn, promote tumor growth, survival, drug resistance, bone 
resorption, and metastases.
The interplay between tumor cells and immune system has a crucial role in this process. Indeed, 
tumor development causes a dysregulation of the physiological cytokine milieu, affecting the effec-
tors of cellular and innate immunity, ultimately tipping the balance between immunosuppression 
and immune stimulation that sustains the disease progression (1).
Recently, Notch signaling has emerged as a key regulator of the cellular relationships within the 
tumor microenvironment (TME). The Notch system comprises a family of transmembrane receptors 
Table 1 | Effects of Notch signaling on the cytokine milieu and the immune system.
Notch pathway member Cytokine Main functions Cancer type immune mediators Reference
Notch1 TGFβ Immunosuppression, anti-inflammatory, epithelial- 
to-mesenchymal transition, angiogenesis
– DC, Treg (7, 8)
Dll4 TGFβ as above Lung carcinoma MDSC (9)
Notch3, Jagged1 IL-6 as above Breast cancer MDSC (10–12)
Unknown CXCL12 Migration, proliferation, angiogenesis Multiple myeloma M2 (13, 14)
Unknown CXCL12 as above Ovarian cancer T lymphocyte (15, 16)
Unknown CXCL12 as above Hepatocellular 
carcinoma
Treg, M2 (6, 17)
Dll family, Jagged1/2 IL-10 as above – Th1 (18)
Unknown IL-10 as above Melanoma, lung 
carcinoma
TAM (19–21)
Dll family IL-10 Immunosuppression, anti-inflammatory – DC, Th1 (22, 23)
Jagged1/2, Notch1 IL-4 as above – Th2, DC (24–26)
Dll4 IL-4 Immunosuppression – TAM (27)
Dll4 IL-17 as above – γδT cell (28)
Unknown IL-17 as above Oral cancer CD4+ T, Th17 (29)
Notch1, Jagged2 CCL5 Proliferation, invasion, metastasis Breast cancer TAM M2 (30)
Jagged1 IL-1β, CCL2 Pro-inflammatory, proliferation Breast cancer TAM (31, 32)
Notch1 CCL2 Proliferation Lung carcinoma Mo-MDSC macrophage (33)
Jagged1 IFN-γ Killing immunological functions – DC, T cell (34)
Jagged2 IFN-γ as above Lymphoma NK (35)
Notch1, Notch2 IFN-γ as above – CD4+ T, CD4+ Th1, CD8+ T (36–38)
Dll1 VEGF Angiogenesis, immunosuppression Lung carcinoma T cell (39)
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(Notch1–4), activated by the interaction with five membrane-
bound ligands (Jagged1–2 and Dll1–3–4) present on adjacent 
cells. Ligand binding results in Notch cleavage by two proteases, 
ADAM and γ-secretase. These cleavages release Notch intracel-
lular domain (ICN) from the plasma membrane, allowing it to 
translocate into the nucleus, where it regulates the transcription 
of a plethora of target genes in a transcriptional complex with the 
CSL (CBF-1/suppressor of hairless/LAG-1, also known as RBP-Jk), 
mastermind-like (MAML1–3) coactivator, and other proteins 
(2). Besides this canonical Notch pathway, in oncogenesis and 
inflammation, it has been described a non-canonical Notch 
signaling which is γ-secretase independent (3). Notch signaling is 
tightly controlled by several mechanisms, including degradation 
mediated by the proteasome and lysosome machineries (4, 5). 
The cancer-related aberrant activation of Notch pathway affects 
the biology of the single tumor cell and its interaction with the 
surrounding microenvironment (6).
In this review, we analyze how the dysregulation of the Notch 
pathway in the tumor niche skews the local cytokine milieu 
(Table 1), shaping the immunological landscape, and we describe 
the outcomes of this process on tumor growth, progression, senes-
cence, and metastases illustrating the different molecular mecha-
nisms and mediators operating in the distinct cellular contexts.
NOTCH SiGNaliNG PROMOTeS  
aN iMMUNOSUPPReSSive TMe
The TME is characterized by the prevalence of anti-inflammatory, 
immunosuppressive cytokine milieu. The production of an immu-
nosuppressive secretome often requires Notch signaling activa-
tion. In this chapter, we explore the role of Notch as a positive 
regulator of the most important anti-inflammatory cytokines, 
such as transforming growth factor-β (TGF-β), interleukin 10 
(IL-10), interleukin 4 (IL-4), and IL-6. The role of CXCL12 and 
of receptor activator of nuclear factor kappa-B ligand (RANKL) 
will be discussed as well.
TRaNSFORMiNG GROwTH FaCTOR-β
Transforming growth factor-β is expressed at high levels in sev-
eral malignancies, where it correlates with poor prognosis (40). 
The main source of TGF-β in cancer is tumor and stromal cells, 
but it may also be released following bone extracellular matrix 
remodeling mediated by bone-associated tumors (41).
Transforming growth factor-β supports tumor progression 
through several mechanisms. The activation of TGF-β receptor 
promotes chemoresistance and angiogenesis in breast, prostate, 
gastric, and colon cancer. In addition, TGF-β is also a key player 
in epithelial-to-mesenchymal transition (EMT) (42).
Transforming growth factor-β is best known for its potent 
immunosuppressive activity that affects both cells of the innate 
and adaptive immunity (43–46).
The crosstalk between TGF-β and Notch triggers the TGF-β 
immunosuppressive activity in several contexts. TGF-β is a well-
known inhibitor of DC maturation and, upon stimulation of 
TGF-βRI receptor, the active form of Notch1 can boost TGF-βRI 
signaling in DCs by binding Smad3. The interaction of Notch1 with 
Smad3 promotes the translocation of the latter into the nucleus 
and induces the transactivation of Smad target genes (7, 42). 
Moreover, Ostroukhova et  al. demonstrated that T-reg cell-
derived TGF-β inhibited the activation of effector T cells through 
the Notch target, HES1. In vivo experiments confirmed that this 
inhibitory effect of Tregs on the activation of effector T cells may 
be reverted by the treatment with anti-Notch1 antibodies (8).
In lung carcinoma, Notch mediates the pro-tumoral effect 
of TGF-β secreted by CD11b+ Ly6C+ Ly6G− myeloid-derived 
FiGURe 1 | Transforming growth factor-β (TGF-β) and receptor activator of nuclear factor kappa-B ligand (RANKL) cooperate to suppress the immune response in the 
bone marrow. 1. In bone-associated cancers, the activation of Notch may be promoted by Jagged1/2 ligands overexpressed by cancer cells; one of the outcomes of 
Notch overactivation is to increase RANKL expression (52). 2. RANKL represents the main osteoclastogenic factor and promotes osteoclasts (OCLs) differentiation and 
bone resorption (53). 3. In addition, RANKL plays immunoregulatory functions. RANKL may activate its receptor RANK, which is overexpressed by DCs and, in turn, boosts 
DCs ability to induce the expansion of the local Treg population promoting tolerance to tumor antigens (54). 4. One of the outcomes of the increased bone resorption is the 
release of TGF-β from the extracellular matrix (55). 5. TGF-β can be also secreted by tumor and stromal cells and by myeloid-derived suppressor cells (MDSCs) in the tumor 
microenvironment (TME). Its immunosuppressive effects may be promoted by Notch signaling (see text for details) (41, 51). 6. In specific contexts, such as breast 
cancer-derived bone metastasis, TGF-β released by cancer cells mediates bone remodeling and stimulates the overexpression of Jagged1 in tumor cells. Jagged1 present 
on cancer cell surface, in turn, triggers Notch activation in OCLs and osteoblasts (OBLs), promoting the development of tumor-associated bone disease (56).
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suppressor cells (MDSCs). MDSCs are a heterogeneous popula-
tion of immature myeloid cells that can inhibit T cell responses. In 
lung carcinoma, MDSCs suppress CD4+ and CD8+ T cell acti vity 
(47), secrete TGF-β, which promotes neoplastic cells proliferation 
and the expression of Dll4. MDSC-derived Dll4 activates Notch in 
lung carcinoma cells, boosting TGF-β signaling by binding and 
activating Smad proteins. Consistently, lung cancer cells treated 
with the Notch inhibitors, DBZ and DAPT, showed a reduced 
response to TGF-β and a decreased cell growth, indicating that 
at least in part TGF-β pro-tumorigenic functions are Notch 
dependent, and suggesting that targeting Notch may represent a 
promising therapeutic strategy to antagonize TGF-β (9).
Finally, it is worth mentioning that the cooperation between 
TGF-β and Notch pathway, on top of altering the immune 
surveillance, promotes EMT (6, 42) in different malignancies, 
such as ovarian cancer (48) and squamous cell carcinoma (49). 
Here, high levels of ICN1 seem to cooperate with the TGF-β 
pathway in the tumor milieu, favoring Smad2/3 phosphorylation, 
and finally promoting EMT and the survival of tumor-initiating 
cells (49). The molecular basis of this process is not fully under-
stood, but its implications in cancer progression are clear. EMT 
process modifies tumor cell behavior, reducing the adhesion to 
neighboring cells, promoting the invasion through the basement 
membrane, and finally allowing metastatic dissemination (50).
Finally, TGF-β may also positively regulate the Notch path-
way through different mechanisms (Figure 1). In breast cancer 
bone metastasis, Jagged1 acts as a downstream mediator of 
TGF-β oncogenic signal, contributing to a positive feedback 
FiGURe 2 | The interplay between IL-6 and Notch affects the anticancer immune response. 1. The overexpression of Notch ligands, Jagged1 and Jagged2 by 
tumor cells promotes the activation of the Notch signaling in the tumor microenvironment (TME), boosting IL-6 secretion by the same cancer cells and by the 
neighboring stromal cells (62). 2. On the other hand, IL-6 increases the expression of Jagged1 and Notch3 in tumor cells (64). 3. High IL-6 levels in the TME 
promote tumor cells growth, resistance to therapy, osteoclastogenesis, and contributes to the development of an immunosuppressive niche. Indeed, the activation 
of IL-6R on immune cells causes the polarization of M2 macrophages. 4. The differentiation of CD4+ T cells into interleukin 4 (IL-4)-producing Th2 cells. 5. The 
increased differentiation of pro-inflammatory Th17 cells. 6. The development of interleukin 10 (IL-10)-producing regulatory DCs (65). 7. An alternative source of IL-6 
is represented by myeloid-derived suppressor cells (MDSCs). MDSCs support tumor stem cell maintenance by a combined action of IL-6 and nitric oxide (NO). 
Indeed, MDSCs, through the release of IL-6, promotes the phosphorylation of signal transducer and activator of transcription 3 (STAT3) essential for maintenance  
of cancer cell stemness, and by producing NO indirectly activates the Notch pathway. Notch activation, in turn, causes prolonged STAT3 activation (12).
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in cancer-mediated bone destruction. Cancer-derived TGF-β 
mediates bone remodeling and stimulates the overexpression of 
Jagged1 in tumor cells. In turn, Jagged1, located on the cancer 
cell surface, triggers Notch activation in osteoclasts (OCLs) and 
osteoblasts (OBLs). The net effect of this process is OCLs dif-
ferentiation and activation, and OBLs inhibition (51). This is in 
agreement with the evidence that Jagged1 forced expression can 
restore the ability of xenografted breast cancer cells to form bone 
lesions in Smad knock-out mice (10).
iNTeRleUKiN 6
IL-6 has been proposed as a therapeutic target in several tumors, 
since it represents one of the most abundant soluble factors in 
the TME (57). It is associated with poor prognosis and is present 
at high concentrations in the serum of patients with different 
malignancies, including multiple myeloma, breast, colon, gastric, 
pancreatic, esophageal, hepatic, cervical, and renal cancer (55, 58).
IL-6 signaling has been shown to promote tumorigenesis by 
regulating cancer metabolism, increasing cancer cell growth and 
self-renewal, as well as resistance to apoptosis, boosting invasive-
ness and metastasis, regulating angiogenesis (57), and sustaining 
RANKL expression and bone resorption (59). IL-6 may also regu-
late the immune system by playing a role as pro-inflammatory 
and anti-inflammatory cytokine (59). Here, we will focus on the 
immunosuppressive effect, more frequently described in cancer, 
while we will refer to the pro-inflammatory, immune-activating 
effect of IL-6 in the chapter on cancer cell senescence.
The activation of Notch pathway induces the expression of 
IL-6 in malignant cells of different tumors, i.e., in colon cancer, 
stimulates tumor cell proliferation (60), and in luminal breast 
cancer, it promotes self-renewal and drug resistance (61). In other 
malignancies, such as multiple myeloma (62) and gastric cancer 
(63), Notch ability to drive IL-6 secretion has been observed also 
in the surrounding stromal cells of the TME. The increase of IL-6 
in the TME promotes tumor cell growth and disease progression 
(Figure 2).
The interplay between IL-6 and Notch has been studied 
in depth in multiple myeloma and breast cancer. Myeloma 
cells colonize the bone marrow (BM), which represents a safe 
harbor, where tumor cells find an ideal environment for their 
proliferation and survival (66). In the BM of multiple myeloma 
patients, IL-6 is produced by tumor cells, BMSCs, and cells of 
the myeloid lineage, such as eosinophils, macrophages, DCs, 
and mast cells (67). Recently, we demonstrated that in multiple 
myeloma the overexpression of Notch ligands, Jagged1 and 
Jagged2, combined with the expression of Notch receptors, 
activates the endogenous Notch signaling, which drives IL-6 
5Colombo et al. Notch and Cytokines
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secretion. Moreover, myeloma cell-derived Jagged may activate 
Notch receptors in BMSCs via heterotypic interaction and pro-
mote IL-6 secretion, ultimately causing IL-6 levels to increase in 
the BM microenvironment (62). In myeloma progression, IL-6 
promotes tumor cells growth, osteoclastogenesis, resistance to 
therapy (62, 67, 68), and, importantly, contributes to the develop-
ment of an immunosuppressive milieu in the BM niche (67). The 
mechanism underling the immunosuppressive activity of IL-6 in 
multiple myeloma is complex and still poorly understood. The 
outcomes of IL-6 activity on immune cells include favoring the 
polarization of M2 macrophages, inhibiting Th1 differentiation, 
and redirecting CD4+ T cells differentiation into IL-4-producing 
Th2 cells, promoting the differentiation of immature DCs in 
IL-10-producing regulatory DCs (65). Moreover, IL-6, together 
with TGF-β, affects the balance between Tregs and Th17 cells, 
reducing the tumor-suppressive Tregs and promoting the differ-
entiation of pro-inflammatory, Th17 cells (67). Nonetheless, the 
final outcome of Th17 cells in multiple myeloma is not clear. In 
different tumor settings, Th17 cells may either positively regulate 
immune surveillance or promote tumor cells survival (67, 69). 
Moreover, IL-6 favors the polarization of M2 macrophages. 
These cells play a crucial role in connecting cancer with inflam-
mation and support tumor cells proliferation, invasion, and 
metastasis development, promote angiogenesis, and hamper 
T-cell-mediated antitumor immune response, thus sustaining 
tumor progression (70).
In breast cancer, high IL-6 is associated with poor prognosis 
(56). Several biological effects triggered by IL-6 are mediated by 
Notch signaling activation. Indeed, IL-6 requires Notch3 acti-
vity to promote cancer cell invasion and self-renewal (11, 71). 
This is not the only way by which IL-6 and Notch cooperate 
in this malignancy. Interestingly, MDSCs are another source of 
IL-6 in the tumor niche. These cells contribute to tumorigen-
esis by suppressing T  cell activation and promoting stem-like 
properties of breast cancer cells. These effects are mediated by 
MDSCs ability to promote the interplay between the Notch 
signaling and IL-6-dependent signal transducer and activator 
of transcription 3 (STAT3) activation in cancer cells. MDSCs 
produce IL-6, which promotes the phosphorylation of STAT3, 
and the production of nitric oxide, in turn activating Notch 
signal, which causes prolonged STAT3 activation and supports 
cancer cell stemness (12).
The crosstalk between Notch pathway and IL-6 in breast 
cancer cells seems to be mediated also by NF-κB. Indeed, the 
activation of the non-canonical Notch signaling mediated by two 
components of the NF-κB cascade, IKKα and IKKβ, has been 
reported to upregulate IL-6 expression (72). The relevance of the 
non-canonical-Notch/NF-κB/IL-6 axis stems from the evidence 
that, while canonical Notch4 is necessary for the development of 
mammary glands, non-canonical Notch4 signaling is related to 
breast cancer tumorigenesis (73).
The interplay between Notch and IL-6 is even more com-
plicated in breast cancer-associated bone metastasis. Here, the 
overexpression of Jagged1 activates Notch signaling in BMSCs, 
promoting the secretion of IL-6. In turn, IL-6 increases the 
expression of Jagged1 and Notch3 in tumor cells (64) and stimu-
lates tumor growth and drug resistance (10).
Although the above reported findings do not provide a direct 
evidence, they allow us to hypothesize that the remodeling of the 
immune system may represent one of the mechanisms through 
which IL-6 and the Notch pathway cooperate to promote multiple 
myeloma and breast cancer progression.
CXCl12
CXCL12, known also as stromal-derived factor 1 (SDF1), binds 
two chemokine receptors: CXCR4 and CXCR7. We will focus on 
CXCR4 since it represents the most widely expressed chemokine 
receptor in human malignancies and it is a crucial player in the 
plasticity and alteration of the TME both in hematologic tumors, 
such as multiple myeloma, acute myeloid leukemia, T cell acute 
lymphoblastic leukemia (T-ALL), and in solid tumors such 
as ovarian, prostate, colon, brain, breast, and bladder cancer 
(74–76).
CXCR4 signaling is upregulated by hypoxia or in response to 
steroid hormones and it is associated with an invasive and meta-
static phenotype (77) due to its involvement in several aspects 
of tumor development and progression such as cell migration, 
proliferation, resistance to apoptosis, angiogenesis, and develop-
ment of metastasis (77–80).
In addition, the CXCR4/CXCL12 axis plays also a key role 
in inducing TME tolerogenic polarization in different types of 
cancers, although the exact mechanism has not been elucidated. 
Feig et al. demonstrated that in pancreatic cancer the blockade 
of CXCL12 produced by tumor-associated fibroblasts promotes 
CD3+ T-cells recruitment and restores the sensitivity to the 
antagonists of the checkpoint inhibitors programmed cell 
death-1 (PD-1) and cytotoxic T-lymphocyte-associated protein 
4 (CTLA-4) (81). Accordingly, Chen et al. showed that CXCR4/
CXCL12 blockade synergized with anti-PD-L1 immunotherapy 
in advanced hepatocellular carcinoma (82), while a similar 
mechanism was recently reported in an in vivo model of colorectal 
cancer (83). This synergy is relevant since, although checkpoint 
inhibitors have emerged as effective new therapeutic approaches 
in cancer, the response rate in patients is still variable and could 
benefit from a combinatory therapy (84).
The cooperation between Notch and CXCR4/CXCL12 has 
been reported in hematologic and solid malignancies. We recently 
showed that the expression of CXCR4 and CXCL12 in multiple 
myeloma cells is positively regulated by Notch signaling and 
may be impaired by γ-secretase inhibitors (13). The activation of 
Notch signaling in multiple myeloma is due to the contemporary 
expression of Notch ligands and receptors (13). Distinct reports 
indicate that activated Notch promotes CXCR4 gene expression 
by binding to CXCR4 regulative regions and transactivating its 
transcription (13, 85). CXCR4/CXCL12 blockade results in a 
decreased tumor cell proliferation and survival and, importantly, 
in the loss of myeloma cells ability to colonize the BM in vivo (13).
The interaction between Notch, CXCL12, and CXCR4 might 
also have a further outcome since high CXCL12 levels in the 
multiple myeloma niche increase the M2 macrophage popula-
tion in the immune cell infiltrate. Indeed, CXCR4 directs the 
recruitment of monocyte precursors at the tumor site, and M2 
macrophages from the BM of myeloma patients express higher 
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levels of CXCR4 compared with patients with the benign form of 
monoclonal gammopathy of uncertain significance and healthy 
individuals (14). Recently, Fabbri et al. demonstrated that also in 
B-cell chronic lymphocytic leukemia Notch1 is able to directly 
regulate CXCR4 expression (86), while in other hematological 
malignancies characterized by Notch1 hyperactivation, such as 
T-ALL, no Notch1-dependent regulation has been observed, but 
a cooperation the two pathways. Indeed, CXCR4 genetic deletion 
in murine hematopoietic progenitors abrogated ICN1 ability 
to induce leukemogenesis (87), but DAPT treatment failed to 
inhibit CXCR4 expression either in cell lines or primary cells 
(88), suggesting that an indirect and more complex mechanism 
of cooperation between these two pathways may be crucial in 
promoting tumor progression.
Among solid tumors, ovarian cancer shows a cooperation 
between Notch and CXCR4 signaling. Indeed, DAPT-mediated 
Notch inhibition causes a decrease in tumor cells growth and 
migration through the downregulation of CXCR4 and CXCL12 
expression (15). By regulating this chemokine system, Notch 
might influence also the immunosuppressive function exerted 
by CXCR4 signaling in ovarian cancer. Indeed, CXCL12/CXCR4 
blockade reduces infiltrated Tregs, increases the presence of 
IFN-γ+/IL-10+ T CD4+ and CD8+ lymphocytes, and supports 
spontaneous humoral and cellular antitumor responses (16). 
Similarly, in hepatocellular carcinoma, characterized by persis-
tent Notch activation (6), hypoxia may induce CXCL12 upregula-
tion, that in turn promotes the recruitment of Tregs and M2-type 
macrophages (17). This suggests that the collaboration between 
CXCR4/CXCL12 and Notch might induce an immunosuppres-
sive TME involving various types of immune cells among which 
Tregs and M2 macrophages.
ReCePTOR aCTivaTOR OF NUCleaR 
FaCTOR KaPPa-b liGaND
RANKL is a member of the tumor necrosis factor (TNF) family 
of cytokines. Its deregulation is particularly relevant in bone-
associated cancers (primary or secondary) due to its involvement 
in the maturation of monocyte in OCLs (53) and the resulting 
associated osteolysis. The increase in RANKL levels characterizes 
almost all bone-associated cancers such as multiple myeloma and 
metastases derived from primary tumors which spread to the 
skeleton, i.e., carcinomas of the prostate, breast, lungs, thyroid, 
bladder, and kidneys as well as melanoma (89).
Indeed, one of the outcomes of cancer cells localization in the 
BM is the unbalance between bone destruction and formation 
due to altered differentiation and activity of OBLs and OCLs (90). 
This dysregulation is caused by an increased secretion of RANKL 
by neighboring stromal cells and infiltrating Th17, Tregs and 
DCs (91), and leads to the development of osteolytic lesions that, 
not only affect patient’s quality of life, but also promote tumor 
growth, survival, metastasis formation, and the development of 
pharmacologic resistance (89, 90, 92, 93) (Figure 1).
Notch pathway dysregulation is involved in several bone-
associated tumors. Results from our group and the group of Kang 
(10, 52) showed a similar situation in multiple myeloma and breast 
cancer. In both cases, tumor cells overexpress the Jagged ligands 
and are able to activate the Notch2 receptor in OCL precursors 
promoting their differentiation, that finally results in increased 
bone resorption and in the development of bone disease (10, 52). 
We also showed that in myeloma cells Notch activity positively 
influences the release of RANKL, while Notch inhibition, 
mediated by gamma secretase inhibitor (GSI) or Jagged ligands 
knockdown, downregulates RANKL secretion with consequently 
decreased OCL differentiation and activity (52).
Myeloma-derived RANKL promotes osteoclastogenesis by 
activating in OCL precursors two major pathways essential for 
their differentiation. NF-κB is triggered by RANK and Notch 
signaling is promoted as a consequence of an increase in the 
expression of Notch2, that in turn is activated by Jagged ligands 
expressed on myeloma cells (52, 94).
Another Notch-dependent source of RANKL in the BM 
niche is represented by osteocytes. In these cells, Notch signal-
ing can be activated by the interaction with myeloma cells. As 
a consequence, Notch activity hampers osteocytes viability and 
promotes RANKL and sclerostin secretion that, in turn, supports 
the recruitment of OCL precursors (95).
Although Notch may act as a regulator of the balance between 
OCL and OBL/osteocyte activity, up to now it has not been 
investigated if Notch controls also other RANKL activities. 
Indeed, RANKL is involved in the shaping of the immune system 
operated by cancer cells in different tumors. RANKL favors 
the expansion of the local Treg population in bone metastatic 
prostate cancer (96), promotes M2–macrophages polarization 
in breast cancer models of lung metastasis (97, 98), interferes 
with NK anticancer activity in acute myeloid leukemia (51), is 
necessary for T cell tolerance in a melanoma model (99), where 
successful results were obtained by a combinatory treatment of 
RANK/RANKL blockade with anti-CTLA-4 (100). The positive 
results of preclinical studies induced to design clinical trials 
to evaluate the potential combinatorial effect of anti-RANKL 
monoclonal antibodies and immune checkpoint inhibitors (101). 
Interestingly, all tumors in which RANKL exerts an immunosup-
pressive activity share a recognized oncogenic activity of Notch, 
suggesting a collaboration of Notch and RANK also in hampering 
the antitumor-immune response.
iNTeRleUKiN 10
Interleukin 10 is an immunosuppressive anti-inflammatory 
cytokine produced by various types of cells during the immune 
response. IL-10 signaling requires the assembly of a two-receptor 
complex consisting of two copies each of IL-10R1 and IL-10R2 
chains; IL-10 receptor binding activates the JAK signal transducer 
and STAT pathway (102).
Interleukin 10 is produced by Th2 cells and monocytes, as well 
as by subsets of T cells, namely CD4+ CD25+ Foxp3+ (Tregs) and 
CD4+ CD25− Foxp3− type 1 regulatory (Tr1), Th1 and CD8+ 
T  cells, B  cells, macrophages, DCs, eosinophils, and mast cells 
(103). Tumor cells produce large amounts of IL-10 that contrib-
utes to tumor progression; in most types of cancers, serum IL-10 
levels correlate with disease severity (104, 105). In TME, IL-10 
secreted by immune and malignant cells activates an autocrine 
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loop that relies on IL-10 receptor and induces the upregulation of 
oncogenes, including cancerous inhibitor of protein phosphatase 
2A and MYC (106).
Interleukin 10 released in TME exerts its immunosuppressive 
function in different ways: (1) unbalancing Th1 vs Th2 tumor-
specific immune responses; (2) mediating the differentiation and 
activation of Tr1 cells involved in immunosuppression (107, 108); 
(3) inhibiting the production of pro-inflammatory cytokines and 
mediators such as IL-1, IL-6, IL-12, and tumor necrosis factor 
α (TNFα) by macrophages and DCs; (4) preventing the differ-
entiation of DCs from monocytes and their maturation (109). 
In particular, IL-10 downregulates MHC-II on DCs and the co-
stimulatory molecules CD80 and CD86 on macrophages (110); 
therefore, DCs display a defective antigen presentation and fail to 
activate cytotoxic T cells (111). Collectively, these effects promote 
the progression in different tumor such as ovarian carcinoma, 
lymphoma, and melanoma (102, 112).
Recently, an antithetic immunostimulatory function of IL-10 
has been reported, too. Indeed, IL-10 may also promote the 
proliferation of CD8+ T cells (113), the differentiation of plasma 
cells along with the prolongation of their survival, the prolifera-
tion of NK cells, and their production of IFN-γ upon stimulation 
with IL-18 (114, 115). It is possible that the overall effect of IL-10 
depends on the specific tumor type and TME, therefore a targeted 
therapy directed to IL-10 should carefully consider the possible 
dual immunosuppressive and immunostimulatory role of this 
cytokine.
The Notch–IL-10 axis is generally involved in self-limitation 
of immune response. Rutz et  al. showed that Notch signaling, 
in synergy with IL-12 or IL-27, stimulates Th1  cells to release 
large amounts of IL-10, that contribute to self-limitation of Th1 
immunity by hampering the inflammatory potential of Th1 cells 
(22). Interestingly, only Dll, but not Jagged ligands expressed by 
DCs are able to trigger Notch receptors located on T cells surface 
and activate IL-10 production in vitro and in vivo (22, 23).
Recently, a negative feedback regulation of hepatic inflam-
mation mediated by the Notch–IL-10 axis was also reported. 
Hepatic inflammation is associated with the expression of Dll and 
Jagged ligands in liver sinusoidal endothelial cells that, in turn, 
activates Notch signaling in Th1 cells, with a consequent increase 
in HES1 and Deltex-1 expression (18). Notch activation triggers 
the production of IL-10 in Th1 cells causing their switch from an 
inflammatory to an immunosuppressive function. Consistently, 
Notch-deficient CD4+ T cells express lower IL-10 levels in the 
presence of liver sinusoidal endothelial cells, leaving the expression 
of Th1 cytokines, such as IFN-γ and TNFα, unaltered (18). We 
speculate that this mechanism of self-limitation of T-cell response 
in inflamed liver might also occur in hepatocellular carcinoma 
since it arises in more than 90% of cases as consequence of hepatic 
injury and inflammation (116).
So far, we have reported an inhibitory role of the Notch–IL-10 
axis on the immune system mediated by Th1  cells and T  cells 
activation, but unexpectedly, this axis also acts to switch tumor-
associated macrophages (TAMs) to the inflammatory, antitumor 
phenotype M1, thereby increasing the antitumor immune 
response. Indeed, the conditional expression of ICN in mac-
rophages of a transgenic murine model induces the conversion 
of TAM from M2 to M1 phenotype by inducing the expression 
of miR-125a, resulting in TNFα and IL-12 secretion and reduced 
release of IL-10 and TGF-β. These macrophages exhibited strong 
antitumor activities in transplanted tumors (19). Conversely, 
Notch blockade by GSI, small interfering RNA, or RBP-Jk dele-
tion switches macrophages to M2 phenotype, characterized by the 
ability to produce IL-10 and an attenuated capacity of activating 
Th1 cells (20, 21). Consistently, T cells activated by RBP-Jk−/− 
macrophage showed a reduced cytotoxic activity against mela-
noma cells when compared with wild-type macrophages (20).
iNTeRleUKiN 4
In the TME, IL-4 is produced by tumor cells, mast cells, activated 
Th2 cells, eosinophils, basophils, and MDSCs (117, 118). A close 
relationship between tumor progression and IL-4 produced by 
tumor-infiltrating Th2 lymphocytes has been found in several 
malignancies such as non-small cell lung carcinoma, breast 
cancer, renal cell carcinoma, prostate cancer, and others (117). 
Moreover, enhanced expression of the IL-4 receptor (IL-4R) has 
been reported in various neoplastic tissues, i.e., glioblastoma, 
malignant melanoma, head and neck cancer, renal cell carcinoma, 
breast, prostate, ovarian cancer, and bladder cancer (117, 119).
Interleukin 4 signaling supports cancer cell proliferation and 
survival (120). Moreover, IL-4 contributes to suppress the anti-
tumor immune response by acting at different levels on adaptive 
and acquired immune system (121).
Although no evidence has been reported of an interaction 
between Notch and IL-4 in cancer cells, Notch signaling plays 
a key role in activating IL-4 expression in different cellular 
components of the TME. A Notch/RBP-Jk binding site has been 
identified in the 3′ end of the IL-4 gene, suggesting that the 
Notch pathway has the ability to directly regulate IL-4 expression 
(122); moreover, Notch has been shown to control IL-4 secretion 
in myeloid progenitors and NK cells probably due to the pres-
ence of two RBP-Jk binding sites in the conserved non-coding 
sequence-2, located downstream the IL-4 gene (123). The coop-
eration between Notch and IL-4/IL-4R pathway also contributes 
to the differentiation and activation of immunosuppressive Th2 
cells. The activation of Notch signaling by DC-expressed Jagged2 
induces Th2 cells differentiation by boosting the expression of 
GATA3, IL-2/IL-2Rα, and IL-4 (24, 124). A previous work from 
Fang et al. suggest that Notch1 is the receptor involved in this 
process, since ICN1 directly regulates GATA3, which is a master 
regulator of Th2 differentiation and promotes IL-4 transcription 
by coordinating chromatin remodeling (25, 125). Sauma et  al. 
demonstrated that IL-4 produced by Th2 cells may also promote 
a positive feedback loop on T cell polarization sustaining Jagged2 
expression in DCs (24).
The existence of a crosstalk between Notch and IL-4 signal-
ing during DCs differentiation is supported by the findings of 
Cheng et al., who showed that Jagged1-induced Notch activation 
causes the accumulation of immature DCs, because of the lack of 
IL-4, which is required for their differentiation (26). Conversely, 
Dll4-mediated Notch activation in macrophages may have an 
antitumor effect as shown by the evidence that Dll4-mediated 
Notch1 activation hampers IL-4-induced M2 polarization and 
FiGURe 3 | Crosstalk between Notch and tumor necrosis factor α (TNF-α) in the tumor environment. TNF-α induces Notch activation through NF-κB pathway in 
tumor cells. 1. TNF-α activates Ikkβ inducing the expression of the Notch target gene HES1. HES1, in turn, inhibits the expression of the anti-inflammatory receptor 
peroxisome proliferator-activated receptor γ (PPARγ) with a consequent increased production of TNF-α, IL-6, and IL-1β, that recruit macrophages and neutrophils in 
the tumor site (135). 2. TNF-α promotes Notch signaling by activating Ikkα, that in turn phosphorylates and inhibits FOXA2, thereby reducing the transcription of the 
target gene Numb, a Notch repressor (136). 3. In tumor-infiltrating myeloid-derived suppressor cells (MDSCs), NF-κB-p65, a key mediator of TNF-α/TNFR signaling, 
transactivates Jagged1 and 2 promoters and induces their expression stimulating the tolerogenic activity of tumor-associated MDSCs (137).
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promotes M1 macrophage apoptosis; the authors suggest that the 
interaction between Notch and IL-4 pathway may involve HES1 
ability to bind STAT3, finally inhibiting IL-4R signaling (27).
NOTCH SiGNaliNG STiMUlaTeS 
CaNCeR-aSSOCiaTeD PRO-
iNFlaMMaTORY CYTOKiNeS
Cancer is tightly associated with chronic inflammation. The 
abi lity of infiltrated immune cells to promote tumor growth, pro-
gression, and immune surveillance may be mediated by several 
pro-inflammatory cytokines and chemokines, including TNFα, 
interleukin 17 (IL-17), IL-1, and CCL2 and CCL5. In the follow-
ing sections, we will describe the interaction of Notch signaling 
with such cytokines and the outcome of their interplay on the 
immune response.
TUMOR NeCROSiS FaCTOR α
Tumor necrosis factor α is a pro-inflammatory and immuno-
modulatory cytokine, member of the TNF/TNF receptor 
superfamily (126). TNFα is one of the most strong activators of 
NF-kB pathway (127). TNFα may be produced in response to 
inflammation and infection by macrophages, lymphocytes, fibro-
blasts, and keratinocytes, but also tumor cells may be a relevant 
source (128).
The pro-inflammatory and immunomodulatory effect of 
TNFα is at the basis of its pro-tumor activity, observed in 
different malignancies including cutaneous, ovarian, pancreatic 
cancer, and tumors of the pleural cavity and the bowel (128). 
High levels of TNFα in the serum have a poor prognosis in 
ovarian, renal, pancreatic, prostate, breast cancer, and chronic 
lymphocytic leukemia (126). The mechanism underlying TNFα 
pro-tumor activity was nicely described in ovarian cancer. 
TNFα released by tumor cells and cells of TME acts through its 
receptor TNFR1 and further reinforces TNFα expression and 
the inflammatory and immune-modulatory network including 
CXCL12, CCL2, IL-6, VEGF, and macrophage inhibitory factor 
(129). This induces the differentiation of myeloid progenitors to 
endothelial cells, extracellular matrix remodeling, and recruit-
ing leukocytes at tumor site for local immunosuppression (128). 
TNFα immunosuppressive function includes downregulation of 
TCR signaling and DC function, promotion of T cell apoptosis, 
activation of Tregs, induction of tumor cell dedifferentiation 
with a consequent reduced expression of immunogenic anti-
gens and impaired recognition by cytotoxic T  cells, impaired 
differentiation of immature MDSCs with increased suppressive 
activity resulting in T and NK cell dysfunction and finally induc-
ing other cytokines that can inhibit cell-mediated immunity 
(130–134).
An interplay of Notch pathway and TNFα has been described 
in several studies (Figure 3). TNFα stimulation may result in the 
transcription of important Notch target genes mediated by the 
activity of NF-kB. In a mouse model of pancreatic cancer, TNFα 
induces the activation of Ikkβ, a component of the NF-κB signal-
ing, that promotes the expression of Notch target genes HES1 
by inducing histone H3 phosphorylation at the HES1 promoter 
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resulting in transcriptional activation. This, in turn, inhibits the 
expression of the anti-inflammatory nuclear peroxisome proliferator-
activated receptor γ (PPARγ), reinforcing the inflammatory 
loop (135). PPARγ repression in pancreatic cancer cells results 
in the constitutive production of pro-inflammatory cytokines, 
including TNFα, IL-6, and IL-1β, relevant in the recruitment of 
macrophages and neutrophils into the tumor site. Consistently, 
in  vivo treatment with a PPARγ agonist, rosiglitazone reduces 
macrophage infiltration (135).
Evidence obtained in liver cancer clearly shows a cooperation 
between TNFα and Notch in inflammation-mediated cancer 
pathogenesis. TNFα regulation of Notch1 signaling is medi-
ated by Ikkα-induced phosphorylation of FOXA2. This causes 
the inhibition of FOXA2 activity as a transcription factor and 
consequently decreases the expression of its target genes includ-
ing Numb. Numb is a well-known Notch repressor, thereby 
the consequence of its inhibition is the increased activation of 
Notch1, that is associated with tumorigenesis (136). Indeed, by 
in  vivo studies on mice that received transplanted tumors har-
boring Numb knockdown Hep3B cells infected with retrovirus 
expressing FOXA2 continued to show tumor growth even in the 
presence of FOXA2. Moreover, a link of IKKα-mediated FOXA2 
phosphorylation to hepatocellular carcinoma tumorigenesis was 
supported by higher levels of IKKα, phosphorylated FOXA2, and 
activated Notch1 in hepatocellular carcinoma specimens respect 
to normal liver tissues (136).
Further studies performed on murine models of Lewis lung 
carcinoma, colon carcinoma, thymoma, and melanoma, showed 
that the expression of NF-kB-p65, a key mediator of TNFα, is 
associated to increased levels of Jagged1 and 2 in tumor-infiltrating 
MDSCs (137), suggesting that TNFα may positively regulate the 
expression of Jagged ligands. Jagged1 and Jagged2 widely affect 
immune system regulation as shown in vivo with humanized anti-
Jagged1/2-blocking antibody CTX014. This treatment affected the 
accumulation and tolerogenic activity of MDSCs in tumors and 
inhibited the expression of immunosuppressive factors arginase 
I and inducible nitric oxide synthase (137). As a consequence, 
tumor-induced T-cell tolerance was reduced and the infiltration 
of reactive CD8+ T cells was increased thus enhancing the in vivo 
efficacy of T-cell-based treatment (137).
Finally, one elegant study showed a complementary effect of 
Notch and TNFα in multiple myeloma-induced bone disease 
(95). The authors showed that co-cultured multiple myeloma cells 
and osteocytes reciprocally activated Notch signaling. Notch acti-
vation in osteocytes induced apoptosis that in a second phase was 
amplified by high levels of TNFα secreted by MM cells. The coop-
eration of the two pathways is further confirmed by the evidence 
that single treatment with GSI-XX or anti-TNFα only partially 
inhibited cell death, whereas the combined treatment completely 
prevented osteocyte apoptosis. The increased apoptosis levels in 
osteocytes not only reduce their bone deposition activity but also 
increase active bone matrix degradation since it is also associated 
with the enhanced expression of the key osteoclastogenic factor 
RANKL (95). This evidence suggests that multiple myeloma cells 
exploit the collaboration of Notch and TNFα signaling pathways 
to induce bone resorption in multiple myeloma and possibly 
RANKL-mediated immunosuppression.
iNTeRleUKiN 17
Interleukin 17 is a family of pro-inflammatory cytokine (includ-
ing IL-17A to F) mainly produced by Th17 cells, a lineage of T 
helper cells defined by their ability to produce IL-17, IL-21, and 
IL-22 (138, 139). Other immune cells may contribute to IL-17 lev-
els, including CD8+ T cells, NK cells, γδ T cells, and neutrophils 
(140). IL-17 engages one of its five cell surface receptors (IL-17 
receptor A to E) and triggers the production of various pro-
inflammatory cytokines and chemokines that recruit monocytes 
and neutrophils to the site of inflammation (141).
The most important role of IL-17 is attributed to its ability to 
stimulate various cell types to produce pro-inflammatory cyto-
kines and chemokines by activating the NF-κB pathway (142–144).
The presence of Th17 cells and the expression of IL-17 have 
been found in almost all tumors (145, 146). Nonetheless, the role 
of IL-17 in cancer is controversial, since both pro-tumoral and 
antitumoral effects have been reported, possibly due to its pleio-
tropic activity. IL-17 may promote tumorigenesis in several types 
of cancer and in different ways: (1) by inhibiting tumor apoptosis 
and promoting tumor proliferation (147–149); (2) by inducing 
tumor–associated stroma to release of the pro-tumoral cytokine 
IL-6 (150); (3) by recruiting macrophages and MDSCs to the 
tumor site (151, 152); (4) by promoting Tregs infiltration into 
tumor tissue through upregulation of CCL17 and CCL22 (153); 
(5) by promoting angiogenesis through the increase of VEGF 
production (154); and (6) by stimulating tumor cells to express 
matrix metalloproteinase-2 (MMP-2) and MMP-9 involved in 
cancer cell invasion (155).
Despite these pieces of evidence, recent studies on cancer 
patients highlight an antitumoral role of IL-17. Indeed, the 5-year 
survival rate in patients with gastric adenocarcinoma (156), 
esophageal squamous cell carcinoma (157), chronic lymphocytic 
leukemia (158), ovarian cancer (159), and cervical adenocarci-
noma (160) displaying increased IL-17 levels was reported to be 
significantly higher than survival in patients with lower IL-17 
expression. The possible mechanisms underlying this effect could 
rely on the positive regulation of the adaptive immune response via 
stimulation of the production of cytokines and chemokines such 
as IFN-γ, CXCL9, and CXCL, recruitment of CD4+, CD8+ T cells 
(159), DCs (157), and neutrophils (161) to tumor sites, stimulation 
of NK cell activity (157), generation and activation of CTLs (162).
The complex array of IL-17 effects on the immune system 
response might explain its dual behavior and, probably, its overall 
outcome may depend on tumor cell type and the surrounding 
TME, including the pattern of immune cells and cytokines. On 
the other side, it cannot be ruled out that opposite effects of IL-17 
reported for the same type of tumor can be due to differences in 
the animal models used or the number of cases, or to possible 
different targets of the performed investigation, including IL-17 
produced only by Th17  cells or by the whole the set of IL-17-
producing subsets of cells.
Notch regulates IL-17 expression affecting the immune cell 
response (Figure  4A). Here, we will report a picture of the 
mechanisms and the outcomes in different immune cell types 
involved in the antitumor response. Dll4-triggered Notch activa-
tion of CD4+ T cells under Th17 skewing conditions (stimulation 
FiGURe 4 | The interaction between Notch and interleukin 17 (IL-17) in different immune cellular settings. (a) Notch signaling stimulates Th17 cell differentiation. 1. 
Dll4, upregulated on DC cells upon TLR activation, in cooperation with skewing cytokines, IL-6 and transforming growth factor-β (TGF-β), activates Notch signaling 
in naive CD4+ T cells inducing the production of IL-17 and Th17-related cytokines, IL-22 and IL-23, and the consequent differentiation in Th17 cells. Dll4-mediated 
Notch activation in naive CD4+ T cells results in the direct transactivation of IL-17 promoter by activating the RBP-Jk/CSL transcription factor (163–165). 2. In 
addition, ICN may also stimulate Th17 cell differentiation by transactivating the promoter of Ror-γt, a transcription factor required for Th17 differentiation and a main 
regulator of IL-17. 3. Jagged1-conditioned DCs produce IL-2 that is required for the production of IL-17 by CD25+ cells (166). (b) Notch signaling in γδ T-17 cells. 
1. Dll4, upregulated on thymic epithelial cells following IL-6 induction, activates Notch signaling in γδ T-17 cells resulting in expression of HES1, that in turn induces 
the production of IL-17 and the development of γδ T-17 cells (28, 167). 2. High level of Dll4 in peripheral tissues, such as the intestine and lung, is enable to activate 
Notch in γδ T-17 cells (28). This results in the production of IL-17, IFN-γ, and tumor necrosis factor α (TNFα) along with the proliferation and activation of peripheral 
γδ T-17 cells and enhancement of their antitumor cytolytic effect (29).
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with IL-6 and TGF-β) is associated with the production of IL-17 
and Th17-related cytokines, IL22 and IL23. Mechanistically, 
Dll4-stimulation mediates the direct transactivation of IL-17 
promoter via RBP-Jk activation. In addition, ICN may also bind 
and transactivate the promoter of retinoic acid-related orphan 
receptor (Ror-γt), a transcription factor required for Th17 differ-
entiation and the main regulator of IL-17 (163, 164). Overall, this 
leads to increased IL-17 production and enhanced differentiation 
of Th17 cell population. Accordingly, Notch signaling blockade 
significantly reduced IL-17 production, even under Th17 skew-
ing conditions (163). Osborne’s group confirmed that IL-17 is a 
direct transcriptional target of Notch in Th17 cells and that the 
differentiation of these cells requires Notch activation (165).
Notch signaling is also involved in promoting an alternative 
DC phenotype able to stimulate T cells to release IL-17. Indeed, 
DCs are known to express both Notch receptors and ligands 
(122). The group of Dallman showed that Jagged1 may trigger 
DC maturation in an alternative way from the LPS-toll-like 
receptor signaling (166). Jagged1-conditioned DCs promotes 
survival, proliferation and increases the suppressive ability of 
Tregs. Moreover, Jagged1-conditioned DCs produce IL-2 that 
stimulates CD25+ T cells to produce IL-17 (166).
The activity of Notch signaling in promoting IL-17 expres-
sion links Notch to the differentiation of another population of 
T  lymphocytes, γδ T-17 cells, a subset of γδ T cells that shares 
many of the Th17 phenotypic markers and effector cytokines 
(IL-17 and IL-22) and has important functions in inflammation 
and antitumor immunity (168–170).
Notch activation is known to be involved in thymic deter-
mination and regulation of the innate function of γδ T-17 cells 
in thymus and periphery (28) (Figure  4B). Specifically, HES1 
induces γδ T-17 cell development and IL-17 production (28). In 
the thymus, IL-6 stimulates thymic epithelial cells to express Dll4 
resulting in Notch activation in γδ T-17 cells (167). In peripheral 
tissues, such as the intestine and lungs, the high levels of Dll4 
expression (171), stimulate a Notch-dependent increase of IL-17 
γδ T cells (28).
The only evidence that links Notch activity to the antitumor 
functions of γδ T-17 in cancer has been reported by Gogoi et al. 
These authors showed that Notch stimulates the activation and 
proliferation of peripheral γδ T-17 cells. Notch inhibition, medi-
ated by GSI, reversed this effect and blocked γδ T-17 cell produc-
tion of cytokines including IFN-γ, TNFα, and IL-17, resulting 
in the decrease of γδ T-17 cell antitumor cytolytic effect on oral 
cancer cell lines (29).
CCl5
The inflammatory chemokine CCL5 and/or its receptor, CCR5, 
are expressed in various human cancers, including breast cancer, 
prostate cancer, ovarian and cervical cancer, gastric and colon 
cancer, melanoma, multiple myeloma, Hodgkin’s lymphoma, and 
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T-acute lymphoblastic leukemia (88, 172–174). Further source of 
CCL5 in TME may be infiltrating leukocytes, BMSCs, mesenchy-
mal stem cells, or tumor-associated fibroblasts (174).
CCL5 may enhance tumor development in multiple ways: 
acting on tumor cells by inducing proliferation, invasion, and 
metastasis, shaping the TME by stimulating the activation of 
carcinoma-associated fibroblasts (CAFs) and OCLs (in bone-
associated cancer or bone metastasis), and shaping the immune 
infiltrate toward immunosuppression by promoting the apoptosis 
of cytotoxic CD8+ T  cells, the recruitment of TAMs, MDSCs, 
eosinophils, mastocytes, CD4+ T cells, and T regulatory cells (174).
Notch has been reported to positively regulate CCL5 expres-
sion in multiple myeloma-associated BMSCs (173) and in breast 
cancer (30). As reported above, BMSC-derived CCL5 together 
with other chemokines results in enhanced myeloma cell viability 
and migration (173). A recent report demonstrates that the axis 
CCL5/CCR5 play a key role in a metabolic feedback loop between 
breast cancer cells and macrophages with important outcomes on 
immune system infiltrate (30). Cancer cells may have a high rate 
of glycolysis even in the presence of oxygen; this effect is known as 
aerobic glycolysis or Warburg effect (175) and results in the pro-
duction of high levels of lactic acid, which in turn decreases pH 
in TME that may confer a proliferative advantage to cancer cells. 
Lactic acid produced by breast cancer cells supports TAM M2 
polarization and their production of CCL5 by increasing Notch1 
and Jagged2 mRNA and protein expression (30). In return, 
TAM-derived CCL5 induces breast cancer cell migration, EMT, 
and promotes aerobic glycolysis via AMPK signaling activation, 
resulting in increased metastatic ability (30).
In conclusion, the crosstalk between lactate, Notch signaling, 
and CCL5 has several deleterious outcomes: increased metastatic 
ability and TAM recruitment. In addition, although no direct 
evidence has been reported, it is conceivable that the increased 
acidification and decreased glucose availability greatly influence 
T  cell metabolic fitness (176), switching the infiltrated T  cell 
populations from cytotoxic to regulatory. Indeed, lactate, directly 
and indirectly, affects T  cell proliferation and activation; while 
low glucose levels hamper the activation of effector T cells and 
induce their apoptosis, thereby favoring the increase of Tregs, that 
is not reliant on high rates of glucose metabolism (176).
NOTCH MaY SHaPe THe COMPOSiTiON 
OF THe iMMUNe Cell iNFilTRaTe bY 
ReGUlaTiNG il-1β aND CCl2
IL-1α and IL-1β are pro-inflammatory cytokines, members of the 
interleukin 1 family. IL-1α is mainly secreted by macrophages, 
neutrophils, and endothelial cells in the acute inflammatory 
response where it collaborates with TNFα to promote systemic 
inflammation and fever. Notably, both IL-1α and IL-1β are crucial 
components of the pro-inflammatory secretory profile of senes-
cent cancer cells as detailed below.
IL-1β is predominantly produced by activated macrophages 
and adipocytes in the TME, although cancer cells may contribute 
to increasing its levels (31, 177). IL-1β production is a two-step 
process involving the production of an inactive IL-1β proprotein 
(pro-IL-1β), followed by its activation induced by caspase-1, a 
component of the activated multiprotein complex called inflam-
masome together with the Nod-like (NALP) and apoptosis-
associated speck-like (ASC) (178).
IL-1β has a pleiotropic and controversial role in cancer. It is 
a crucial mediator of the innate immune response, promotes 
tumor growth, angiogenesis, and metastasis in several tumor 
types including breast cancer, melanoma, non-small-cell lung 
carcinoma, and colorectal adenocarcinoma (177).
Breast cancer represents one of the better-studied models and 
expresses all the members of the IL-1 system, including IL-1α and 
β, antagonist IL-1Ra, and receptor IL-1R (177, 179, 180).
IL-1β transcription is regulated by Notch in cancer cells, dif-
ferently from its regulation in the cells of myeloid lineage, where 
its expression is stimulated by the engagement of toll-like recep-
tors or endogenous danger signals. Studies in breast cancer cells 
clearly demonstrate that Jagged1, ICN1, and ICN3 are required 
for IL-1β transcriptional activation occurring at the RBP-Jk DNA 
binding site at −2,085 from the translation start site (31). Despite 
this direct transcriptional regulation, Zheng et  al. suggest that 
IL-1β transcription may be triggered by a more complicated 
mechanism relying on the activation, mediated by phosphoryla-
tion, of STAT3 and requires an active Notch1 signaling (181).
Through the regulation of IL-1β, Notch may shape the 
immune infiltrate at the tumor site, affecting both the innate and 
the adaptive antitumor immune response. IL-1β is a pleiotropic 
cytokine and its role in cancer might be context dependent even 
if this statement is still under discussion (182) since opposite 
outcomes have been reported ranging from cancer protection to 
cancer progression.
A protective role for IL-1β is reported in models of colon 
cancer associated to colitis, possibly due to the concomitant 
production of IL-18, relevant for intestine healing (183), or in 
a model of epithelial skin carcinogenesis, where the inflamma-
some adapter ASC may play a protective role in keratinocytes. By 
contrast, in the same model of skin carcinogenesis, ASC plays as 
a tumor promoter in myeloid cells (184), and IL-1β and inflam-
masome are crucial for mesothelioma development (185) and 
murine mammary carcinoma progression mediated by myeloid 
recruitment (186).
The pivotal role or Notch in the modulation of immune cells 
infiltrating the TME has been mainly studied in breast cancer. 
Notch regulates the recruitment of TAMs in two different ways. 
It promotes the expression of IL-1β and CCL2 and supports 
monocyte adhesion to blood vessel endothelium in synergy with 
CCL2 that promotes chemotaxis and extravasation (31).
Tumor-associated macrophage infiltration is associated with 
poor prognosis (187) and sustains a cytokine milieu abounding of 
TGF-β, IL-1β, and CCL2 that collaborate to promote monocytes 
recruitment and promotes an immunosuppressive TME. The 
underlying mechanism is complex and involves a synergy of 
tumor cells and TAMs. These cells secrete TGF-β that promotes 
Jagged1 expression in tumor cells. Tumor-derived Jagged, in turn, 
boosts the expression of IL-1β and CCL2 in the same tumor cells 
and in TAMs (32). In addition, Notch activation in tumor cells 
potentiates TGF-β signaling by promoting the secretion of the 
urokinase-type plasminogen activator, that allows the maturation 
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of the immature form of TGF-β released by TAMs and further 
sensitize tumor cells to TGF-β through the upregulation of 
TGFβR1 (31).
A further reinforcement of an immunosuppressive TME in 
breast cancer may be induced by high levels of IL-1β. Indeed, 
high IL-1β levels have been reported to be associated with 
impaired activation of CD8+ T cells and systemic expansion and 
polarization of immunosuppressive neutrophils (32, 188). The 
expansion of this population seems to be owed to IL-1β ability 
to activate IL-17-producing γδ T cells responsible for increased 
systemic levels of G-CSF, a cytokine known for its role in granu-
lopoiesis (188).
The relevance of the interplay between Notch and IL-1β 
is strengthened by the evidence that effective IL-1β and CCL2 
antagonists are currently in clinical review to treat benign inflam-
matory disease, and their transition to the cancer clinic has been 
proposed (31).
The nasty outcomes of the cooperation between Notch and 
IL-1β in cancer may be potentiated by body metabolism, specifi-
cally by leptin, a hormone whose levels are significantly increased 
with obesity. Also in this case, most studies focus on breast cancer, 
where leptin acts as a positive regulator of Notch expression and 
activation in estrogen responsive and triple-negative breast can-
cer (TNBC) cells through canonic JAK2/STAT, MAPK1/2K 1/2, 
and PI3K/AKT, and non-canonic signaling pathways JNK and 
p38 MAP kinases (189, 190).
Here, besides the reported Notch-mediated increases of the 
expression of IL-1β, VEGF, and VEGFR2, the authors demon-
strate that IL-1β signaling is required for the positive regulation 
of Notch receptors induced by leptin (190); moreover, beside the 
immunosuppressive effect of Notch signaling reported above, 
Notch, IL-1β and leptin crosstalk outcome mediates other key 
features including cell proliferation, survival, migration, and 
angiogenesis in breast cancer (190) and likely in other tumors 
including pancreatic and endometrial cancer (189, 191).
Inflammatory TME plays a key role in the self-renewal of 
cancer stem cells (CSCs). In particular, the interplay between 
Notch and IL-1β in TME is reported also to affect CSCs in TNBC 
resulting in increasing their self-renewal. Indeed, metastatic 
TNBC cells in the brain express high levels of IL-1β that stimu-
lates the neighboring astrocytes to express Jagged1. This in turn 
triggers Notch signaling upregulation in CSCs enhancing their 
self-renewal (192).
Concerning CCL2, its production from different cell types, 
such as fibroblasts, OBLs, endothelial cells, and smooth muscle 
cells, is thought to promote cancer growth and metastasis (193). 
Notch pathway has been frequently reported to positively regu-
late CCL2 expression (31), although this effect seems to be cell 
type specific, indeed in experimental liver fibrosis and patients 
with acute-on-chronic liver failure Dll4 is inversely associated to 
CCL2 (194) and in the melanoma cell line M624 silencing of the 
Notch coactivator MAML1 results in CCL2 mRNA and protein 
upregulation (195). The outcome of Notch-mediated positive 
regulation of CCL2 in breast cancer cells in synergy with IL-1β 
has already been described (31). Further noteworthy outcomes of 
the Notch/CCL2 axis are important in the nasty communication 
between tumor cells and BMSCs in the primary tumor site and 
in the metastatic one. Multiple myeloma cells primarily reside 
at the BM, where they get an advantage and induce BMSCs to 
a pro-tumor behavior in different ways, including conveying 
extracellular vesicles containing different stimuli among which 
miRNAs. Tumor-derived miR-146a may induce the activation of 
Notch1 in BMSCs stimulating them to secrete CCL2 and several 
cytokines including IL-8, IL-6, CXCL1, IP-10, and CCL5 that 
enhance myeloma cell viability and migration (173). An elegant 
study by Yumimoto et  al. explored the mechanisms of cancer 
metastasis, showing that lung metastases are promoted by BMSCs 
migrated to the lungs, and identified a trigger of the metastatic 
process in the low expression of the tumor suppressor FBXW7 
in TME, a condition associated with poor prognosis in breast 
cancer patients (33). The FBXW7 role is based on its ability to 
downregulate Notch signaling since it mediates a key step in the 
degradation of ICN (and other oncogenes), acting as substrate 
recognition component in the SCF-type ubiquitin ligase complex. 
In vivo experiments showed that loss of FBXW7 in BMSCs results 
in the accumulation of ICN1, that in turn promotes the secretion 
of CCL2. CCL2 is a chemotactic stimulus for the recruitment of 
Mo-MDSCs and macrophages that, in turn, induce the metastatic 
site to sustain the growth of tumor cells that have already colo-
nized the lungs (33).
NOTCH aND iFNγ COOPeRaTe TO SHaPe 
THe iMMUNe Cell laNDSCaPe
IFN-γ is a key promoter of macrophage activation and induction 
of MHC-II expression. The most important sources of IFN-γ 
are cells of T lineage including CD8+ T cells and Th1 cells, NK 
and NK T cells belonging to the adaptive or the innate immune 
system (196).
The antitumor activity of IFN-γ stems from several distinct 
mechanisms:
(1) tumor-directed anti-proliferative and pro-apoptotic actions, 
based on STAT1 activation and the expression of, respec-
tively, cell cycle inhibitors such as p21 and p27, or apoptotic 
mediators including caspase-1 or Fas and Fas ligand (197);
(2) inhibition of angiogenesis, indirectly induced by a family 
of interferon-induced chemokines with potent angiostatic 
actions, i.e., IP-10, Mig, and I-TAC (197);
(3) potentiation of the killing immunological functions, includ-
ing (a) development of antitumor adaptive immune response 
mediated by (i) IFN-γ ability to direct the appropriate Th1/
Th2 balance by stimulating Th0 cell polarization toward Th1 
and inhibiting Th2 cell differentiation; (ii) IFN-γ-mediated 
stimulation of MHC-I expression by tumor cells with the 
consequent increase of tumor-antigen presentation; (iii) acti-
vation of the tumor cell killing mediated by T CD8+ cells; 
(b) the activation of the host antitumor innate immune 
response, mediated by macrophages and NK cells (197).
IFN-γ has been reported to be a direct transcriptional target of 
Notch; a study performed on Th1 cells demonstrated that Notch 
is recruited to the RBP-Jk-binding elements at an enhancer site 
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of the IFN-γ gene (198). We will briefly describe the role played 
by Notch in regulating the important activity of IFN-γ in the 
regulation of antitumor innate and adaptive immune response 
by examining the outcome on the key cell types involved: DCs, 
NKs, CD8+, and CD4+ T cells.
Concerning DCs, Notch and IFN-γ collaborate to promote their 
maturation and the ability to activate the different T cell subsets. 
Notch positively regulates DC maturation; indeed, Notch ligand 
Jagged1 induces the upregulation of maturation markers, IL-12 
production, and DC ability to promote T  cell proliferation and 
maturation in effector T cell as demonstrated by IFN-γ production 
(34). Moreover, the CD80/CD86 triggered upregulation of IL-6 
secretion, necessary for full T cell activation, occurs through the 
collaboration of Notch and PI3K signaling (199). Finally, Notch 
signaling increases the expression of MHC complexes in DCs, 
necessary for T cell activation.
A great part of the role of Notch signaling in antitumor response 
is due to DC ability to activate Notch signaling in interacting 
lymphocytes through the expression of Notch ligands. Among 
the physiological stimuli promoting the expression of Notch 
ligands in DCs, GM-CSF and CpG DNA have been reported to 
increase Jagged2 expression (35), while LPS induced Jagged1 and 
Dll4 production (200). DC-derived Notch ligands participate in 
the instruction of T helper cells to commit to the Th1 (201), Th2 
(122), Th17 (163), or Treg (202) lineage.
Recent studies showed that NK cells can be activated by DCs 
and macrophages (35, 203, 204) and that Jagged and Dll ligands 
can promote the development or activation of NK cells in vitro 
(205, 206). Kijima and colleagues (35) confirmed in vivo that DCs 
can increase NK cell cytotoxicity by stimulating the activation of 
Notch2 on NK cells through the ligand Jagged2, whose expres-
sion may be stimulated by GM-CSF and CpG DNA. Importantly, 
Jagged2 stimulated NK  cells to increase IFN-γ secretion and 
cytolytic activity resulting in decreased tumor burden in a murine 
lymphoma model (35).
The generation of cytotoxic CD8+ T  cells is essential for 
tumor control. DCs provide key signals to induce the priming 
and activation of CD8+ T cell. Notch pathway has an important 
role in both these processes in human CD8+ T cells. Indeed, the 
activation of Notch2 signaling on CD8+ T  cells, mediated by 
Dll4 or Jagged1 expressed by DCs, is required for the activation 
and proliferation of human CD8+ T cells and for the release of 
effector cytokines including IFN-γ, along with TNFα, perforin, 
and granzyme B (36, 37, 200, 207).
Auderset et al. reported that Notch pathway is involved also in 
the differentiation and activity of the Th1 subset of CD4+ T cells 
(38). Specifically, Notch signaling mediated by Notch1 and/or 
Notch2 induces IFN-γ secretion by CD4+ Th1 cells. Interestingly, 
the involvement of Notch signaling seems to provide a possible 
alternative stimulus for Th1 cell differentiation in the absence of 
the skewing cytokine IL-12 as demonstrated by RBP-Jk ablation 
or in mice expressing a dominant negative MAML transgene 
(208). Indeed, upon LPS stimulation CD8− DC subtype induces 
MyD88-dependent expression of Dll4, which in turn may engage 
Notch on Th1 cells inducing IFN-γ expression, differently from 
LPS effect on CD8+ DCs that results in increased IL-12 expres-
sion (209).
In contrast to the collaboration of IFN-γ and Notch in pro-
moting Th1 cell differentiation, IFN-γ and Notch play antithetic 
roles in Th2 cell polarization. IFN-γ may potentiate the Th1 shift 
by an inhibitory effect on Th2 cell response, while essentially 
Notch antagonizes IFN-γ-induced inhibition of Th2 cell differ-
entiation. A confirmation of this role comes from the evidence 
that upon IFN-γ neutralization Notch activation becomes 
dispensable (198).
veGF aND NOTCH COOPeRaTe TO 
iNDUCe TUMOR aNGiOGeNeSiS aND 
evaSiON FROM THe iMMUNe SYSTeM
VEGF regulates different aspects of tumor progression including 
angiogenesis, but although its role in cancer progression is much 
wider. Recently, an immunosuppressive function of VEGF has 
emerged that protects cancer cells from the increased recruitment 
of immune cells at the tumor site promoted by neoangiogenesis. 
Indeed, if tumor vasculature is key in providing tumor cells with 
oxygen, nutrients, and glucose, along with an escape to enter 
blood circulation allowing tumor metastasis, it also maximizes 
the exposure of tumor cells to the antitumor activity of immune 
cell populations. Thereby, we will detail the interaction of VEGF 
with Notch signaling in regulating these important aspects of 
tumor progression.
VEGF is known as a major pro-angiogenic signaling pathway 
involved in developmental, physiological, and tumor-associated 
angiogenesis. VEGF family consists of six ligands (VEGF-A, -B, 
-C, -D, -E, and placental growth factor) with different affinity to 
the four VEGF receptors: VEGFR1–2–3 and neuropilin 1 (210). 
This family regulates almost all steps of new vessels formation 
including sprouting and intussusceptive angiogenesis, vessel matu-
ration, and differentiation into arterioles, venules, and capilla-
ries (211).
Aberrant sprouting angiogenesis is characteristic of tumor 
vasculature. VEGF and Notch cooperate to control the sprouting 
of new vessels by tightly regulating the balance between tip and 
stalk cells (212) as detailed in Figure 5. Thereby, it is evident that 
increased levels of Notch signaling or VEGF levels in cancer may 
locally alter the vasculature.
Almost all tumors express VEGF and high intratumor and 
serum levels of this cytokine are associated with poor prognosis 
in cancer patients (218, 219). The release of VEGF by tumor 
cells is activated by distinct microenvironmental cues, including 
hypoxia and inflammatory cytokines, or by deregulated onco-
genes and pathways (220). The outcome is an “angiogenic switch” 
with the formation of new vasculature around the tumor, that 
promotes its growth, invasion, and metastasis (221). Moreover, 
new blood vessels have an immunosuppressive effect by express-
ing inhibitory molecules such as programmed cell death ligand 
1 (PDL1) and PDL2, indoleamine 2,3-dioxygenase, the adhesion 
molecule CD31 that may inhibit T  cell activation and immu-
nosuppressive cytokines such as IL–10, IL-6, and TGF-β (222). 
Also, tumor vasculature and high VEGF levels may shape the 
TME by controlling immune cells extravasation, i.e., promoting 
the migration of Treg cells while hampering the infiltration of 
FiGURe 5 | VEGF and Notch interaction in physiological and tumor angiogenesis. Notch controls tip/stalk endothelial cells balance in tight cooperation with VEGF. 
1. VEGF may be produced by cancer cells, for example, in breast cancer cells, leptin through IL-1 and Notch1, induces VEGF/VEGFR-2 upregulation (190), or by 
the neighboring cells of the tumor microenvironment (TME). VEGF engages VEGFR2/3 and neuropilin 1 (Nrp1) receptors on endothelial cells, activating a signaling 
that promotes Dll4 expression and determines the differentiation toward a tip cell type. Dll4 expressed on tip cells triggers Notch signaling in the neighboring cells 
suppressing the tip cell phenotype and inducing the differentiation in stalk cell. Notch activation in stalk cells either decreases VEGFR1/2/3 expression or stimulates 
antiangiogenic soluble splice variant of VEGFR1 (sVEGFR1) leading to a reduced sensitivity to VEGF (213). Oppositely to Dll4, Jagged1 expressed by stalk cells 
antagonizes Dll4-mediated Notch signaling in stalk cells, thereby increasing tip cell number and sprouting (214). 2. B-cell lymphoma cells release FGF4 that engages 
FGFR1 on the endothelial cells. FGFR1 activation induces Jagged1 upregulation that, in turn, triggers Notch2 signaling in lymphoma cells promoting their 
proliferation, tumor aggressiveness, and chemoresistance (215). 3. Notch1 signaling in endothelial cells may be activated by tumor-derived ligands, i.e., Jagged1 
and Dll4 expressed by lung carcinoma and melanoma cells, or by Jagged1 expressed by neutrophils. Notch1 activation promotes endothelial cell senescence and 
expression of the adhesion molecule, VCAM1, that promotes neutrophil infiltration and tumor cell metastasis (216). 4. In models of tumor dormancy of colorectal 
carcinoma and T cell acute lymphoblastic leukemia (T-ALL) it was shown that Dll4 expressed on tumor endothelial cells can trigger Notch3 pathway activation in 
tumor cells conferring tumorigenic properties to the dormant cells (217).
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effector T cells and thereby favoring an immunosuppressive 
cytokine milieu (222).
Tumor vasculature is triggered by the crosstalk between VEGF 
and Notch signaling within the tumor-associated endothelial cell 
(213). High levels of VEGF in TME, derived from the tumor, 
endothelial, stromal cells, and immune cells such as macrophages 
and Tregs, induce an aberrant activation of Notch signaling in 
tumor-associated endothelial cells that promotes the formation 
of new altered vessels by replicating a dysregulated version of 
physiologic angiogenesis (213, 223, 224).
Studies on mouse tumor models confirmed the involvement 
of VEGF/Notch axis in the formation of tumor endothelium that 
supports tumor growth. As reported in Figure 5, tumor-derived 
VEGF induces Dll4 expression in tumor vessels resulting in 
increased number of stalk cells, characterized by high Notch 
activity, at the expense of the tip cells. As a consequence, the 
formed vasculature displays a reduced density, but enhanced ves-
sel diameter and perfusion, and thereby support tumor growth 
(225, 226). Conversely, as expected, the inhibition of Notch in mouse 
models of glioma, lymphoma, fibrosarcoma, colorectal, lung, and 
mammary gland tumors, by systematic retroviral delivery of 
soluble blocking version of Dll4 or anti-Dll4 antibodies increased 
VEGFR expression in endothelial cells, vessel branching and den-
sity of the tumor vasculature that led to reduced tumor growth 
due to poor perfusion of tumor vessels and increased hypoxia 
(226, 227). Consistently, a Notch1 decoy that inhibits the interac-
tion Notch–Dll caused a hypersprouting phenotype, stimulated 
dysfunctional tumor angiogenesis, and hampered tumor growth 
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in xenograft mouse models of mammary, pancreatic, lung tumors, 
and melanoma (228). The relevance of the cooperation between 
VEGF and Dll4-mediated Notch signaling is highlighted by the 
fact that blocking of Notch signaling through Dll4 neutralizing 
antibody increases sensitivity to anti-VEGF therapy and reduces 
tumor growth (225, 227).
High expression of Jagged1 in tumor endothelium destabi-
lizes the tip/stalk balance resulting in a hybrid tip/stalk pheno-
type leading to enhanced sprouting angiogenesis that promotes 
tumor growth (214). In accordance, it was reported that in ovar-
ian cancer murine model targeting Jagged1 in tumor-associated 
stroma mainly composed of endothelial cells and fibroblasts, led 
to reduced tumor microvessel density and tumor growth (229). 
Consistently, Cao et  al. demonstrated that B-cell lymphoma 
cells through FGF4/FGFR1 signaling upregulated Jagged1 on 
adjacent endothelial cells; in turn, Jagged1 activated Notch2 
signaling in the lymphoma cells promoting tumor aggressive-
ness and chemoresistance (215). In line with this evidence, in 
models of tumor dormancy of colorectal carcinoma and T-ALL, 
Indraccolo et  al. demonstrated that endothelial Dll4 regulated 
Notch 3 signaling in tumor cells allowing the escape from tumor 
dormancy (217).
Besides the aberrant Jagged1 expression in tumor-associated 
endothelial cells, also tumor cells overexpress Jagged1 that 
plays role in tumor sprouting angiogenesis and in the release of 
pro-inflammatory chemokines by endothelial cells. Zeng et  al. 
showed that in head and neck squamous cell carcinoma tumor-
derived Jagged1 triggered the activation of Notch in neighbor-
ing endothelial cells, stimulated the sprouting of capillary-like 
formations and significantly increased neovascularization and 
tumor growth in  vivo (230). Consistently, it was demonstrated 
that Jagged1 and Dll4 expressed by lung carcinoma and mela-
noma cells and Jagged1 expressed by neutrophils triggers Notch1 
activation in endothelial cells inducing their senescence along 
with the expression of chemokines and the adhesion molecule 
VCAM1, that favor neutrophil infiltration, tumor cell intravasa-
tion in tumor vessels and metastasis (216).
Kitajewski’s group showed that in mammary gland tumor 
murine model, in which Jagged1 tumor expression was upregu-
lated by ectopic expression of FGF4, Notch inhibition through 
Notch1 decoy disrupted tumor angiogenesis and delayed the 
growth of murine Mm5MT xenografts (231). The same group 
later showed that the interplay between Jagged1 and VEGF pro-
motes tumor endothelial branching along with vascular mural 
maturation that requires the involvement of Jagged1 (228). Using 
Notch1 decoy which specifically inhibits Jagged-class medi-
ated Notch activation, the authors showed that Jagged ligands 
positively regulate angiogenesis by suppressing sVEGFR1 and 
promoting the interaction between mural cells and endothelial 
cells (228). Thereby, selective Jagged blockade using a Notch 
decoy increases sVEGFR1 levels, suppressing sprouting and 
perfusion, and disrupts pericyte and vascular smooth muscle cell 
coverage in tumor endothelium of mouse models of mammary, 
pancreatic, lung tumors, and melanoma, resulting in inhibited 
tumor growth (228).
A recent study on invasive mammary micropapillary carci-
nomas hypothesized also a cooperation of VEGF and Notch in 
tumor lymphangiogenesis. Here, the active form of Notch1 is 
expressed in extra-tumoral lymphatic endothelial cells together 
with a receptor of VEGF-C, VEGFR3, involved in lymphatic 
endothelial cell proliferation, tumor lymphatic invasion, and 
tumor metastasis (232).
So far, we have described a cooperative activity where VEGF 
released in TME positively stimulates tumor angiogenesis by 
regulating Notch signaling in endothelial cells. But, Notch activa-
tion in tumor cells and neighboring cells may positively regulate 
the levels of VEGF released in the TME, with a consequent 
stimulation of angiogenesis, tumor, and stromal cells.
In breast cancer cells, Notch signaling is necessary for leptin-
induced expression of VEGF and VEGFR2 (as detailed above) 
suggesting that Notch is a downstream mediator of leptin-
mediated regulation of breast cancer cell growth and tumor 
angiogenesis (190). Consistently, Notch1 blockade results in 
downregulated secretion of VEGF associated with a reduction 
of tumor angiogenesis and tumor cell invasive abilities (233). 
In pancreatic tumor cells, exogenous Jagged-1 expression 
induced VEGF secretion and increased the invasive pheno-
type of pancreatic cancer cells (234). The Notch–VEGF axis 
is also exploited by tumor cells to shape the surrounding 
BMSCs and activate their angiogenic effect as demonstrated 
by two studies on multiple myeloma. These groups demon-
strate that Jagged2, overexpressed by myeloma cells, induces 
Notch activation in BMSCs, which in turn activates VEGF 
secretion. Secreted VEGF promotes angiogenesis and acts as 
a growth factor for myeloma cell stimulating its proliferation 
(235, 236).
Finally, we must mention that Notch and VEGF signaling 
cooperated in promoting the “vascular niche” formation neces-
sary for CSC expansion. This aspect has been mainly explored 
in CNS tumors. Studies on glioblastoma multiforme (GBM) 
confirmed that Notch plays a role in endothelial control of CSCs. 
Indeed, the inhibition of Notch signaling blocks GBM CSC 
self-renewal by decreasing the number of endothelial cells. In 
turn, the CSC niche promotes angiogenesis, by CSC-mediated 
release of VEGF or through pro-angiogenic cytokines produced 
by tumor-infiltrating lymphocytes, such as Th17 cells, and mac-
rophages (237).
As anticipated VEGF functions in cancer are not restricted 
to tumor angiogenesis. Indeed, VEGF produced in the TME 
sustains tumor progression also playing an immunosuppressive 
role by regulating various types of immune cells, such as DCs, 
T  cells, macrophages, and MDSCs (238). Since many kinds of 
immune cells express VEGF receptors, functions of these cells 
can be regulated by tumor-derived VEGF. For instance, through 
the activation of VEGFR1, VEGF inhibits the maturation and 
activation of DCs with a consequent reduced CD8+ T  cell 
response against tumors such as colorectal, gastric, lung, and 
breast cancer (239–243).
VEGF contributes to suppress antitumor immune response 
interfering with CD4+/CD8+ T cell development and differen-
tiation (244). Tumor-derived VEGF facilitates the infiltration 
and proliferation of Tregs by engaging VEGF receptors, local-
ized on the surface of Tregs (245, 246). It should be noted that 
infiltrated Tregs recruited to hypoxic areas may also contribute 
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to increasing VEGF levels in the TME sustaining also tumor 
angiogenesis (223).
VEGF may affect the myeloid immune cell landscape. Indeed, 
VEGF may attract immature myeloid cells from the BM into the 
tumor where, in cooperation with other factors, such as IL-10 
and TGF-β, induces these precursors to differentiate into M2 
macrophages (247) or may also directly recruit macrophages 
to the tumor site (248). Tumor-derived VEGF stimulates 
MDSCs expansion through binding to VEGRF1; consistently, 
bevacizumab treatment of patients with renal cell cancer showed 
decreased the number of MDSCs in the peripheral blood (249).
Although the respective functions of Notch and VEGF as 
immunomodulators are quite well studied along with their 
interplay in directing tumor angiogenesis, little is known about 
their interaction and collaboration in tumor immune escape. 
A study performed by Huang et  al. confirmed the hypothesis 
that their cooperation may contribute to the tumor evasion of 
immune cell surveillance by demonstrating that Notch-VEGF 
crosstalk affects the immunosuppressive function of T-cells (39). 
In a mouse model, the chronic infusion of VEGF, that mimicked 
the pathophysiologic VEGF concentrations observed in patients 
with advanced-stage cancer, reduced the levels of Dll1 and Dll4 
observed in BM cells (39). Low levels of Dll ligands resulted in 
the suppression of T cell function, observed as a decrease of the 
T/B cells ratio in the spleen. Conversely, the selective activation 
of Dll1-mediated Notch signaling in BM precursors in tumor-
bearing mice resulted in the increase of tumor-infiltrating T cells 
and enhanced activation of Th1-type IFNγ-producing T  cells, 
resulting in tumor growth inhibition.
Finally, VEGF may promote immunosuppression also by 
contributing to activate the immune checkpoints effector, PD-1. 
PD-1 is a T cell surface receptor that limits T cell response inten-
sity to avoid autoimmunity. PD-1 regulates two different steps in 
T cell activation. During DC-mediated activation of T cells, PD-1 
engaged by its ligand, PDL1, expressed on DCs may promote 
apoptosis in effector T-cells and survival in regulatory T  cells, 
resulting in self-tolerance and suppression of T  cell cytotoxic 
activity. Thereby, high levels of PD-1 are involved in immune eva-
sion via induction of T cell exhaustion and tolerance for tumor 
antigens (250). Tumor-derived VEGF has been shown to enhance 
expression of PD-1 on activated CD8+ cells of colon carcinoma 
murine models through VEGFR2 signaling, which could be 
reverted by antiangiogenic agents targeting VEGF-A–VEGFR 
(251). In addition, VEGF may also induce the expression of PDL1 
on tumor-associated myeloid DCs, thus impairing DC-mediated 
T-cell stimulation (252).
Although a direct collaboration of VEGF with Notch has not 
been reported yet in the regulation of immune checkpoint, the 
two pathways clearly act synergistically, since also Notch signal-
ing may play a role in T cell exhaustion. As a matter of fact, Notch 
binds to PD-1 promoter stimulating its transcription in activated 
CD8+ T cells. Thereby, Notch signaling inhibition, induced by 
DAPT or SAHM1, affects PD-1 expression, and restores the func-
tion of effector T cell (253).
Overall, shreds of evidence presented here indicate that the 
interaction between Notch and VEGF influences various cell type 
in TME promoting tumor cell growth, angiogenesis, metastasis, 
and escape from the antitumor immune response. Future works 
are needed to further elucidate a role of the crosstalk between 
Notch and VEGF with particular attention to tumor-associated 
immune suppression since uncoupling this interaction may 
increase the potential of immunotherapy to circumvent the eva-
sion of antitumor immune response.
NOTCH ReGUlaTeS THe CYTOKiNe 
PROFile aSSOCiaTeD TO CaNCeR 
CellUlaR SeNeSCeNCe aND iTS 
OUTCOMe ON iNNaTe aND  
aDaPTive iMMUNe SYSTeM
The evidence reported in the previous paragraphs indicates that 
a complex connection exists between Notch signaling levels in 
tumor and healthy cells populating the TME, the cytokine milieu 
and different outcomes on tumor progression. Recently, it was 
reported that Notch signaling ability to control the profile of 
cytokines secreted by tumor cells may be involved also in cancer 
cellular senescence.
Cancer-associated cellular stress events, such as DNA damage 
or activation of oncogenes, may result in cellular senescence. 
Cellular senescence is a process that leads cells to a permanent 
proliferative arrest during aging, embryogenesis, and cancer 
development.
Senescent cancer cells do not proliferate, and as such they do 
not contribute to the increase in tumor burden, but they may 
remain metabolically active and secrete proteins with either 
tumor-suppressing or tumor-promoting activities (254, 255), 
collectively reported as senescence-associated secretory profile 
(SASP). SASP is composed of inflammatory cytokines such as 
TGF-β, IL-1, IL-6, IL-8, growth factors, including VEGF and 
IGF1, and MMPs similar to those involved in early stage inflam-
mation (255).
On the whole, the phenomenon of senescence may have 
beneficial effects for the host, such as terminal arrest of cancer 
cell proliferation and/or its clearance by immune cells recruited 
through the released cytokines, but often detrimental outcomes 
may prevail since the secreted senescence-associated cytokines 
feed non-senescent neighbors inducing their growth or creating 
an immunosuppressive environment that hampers the antitumor 
activity of the immune system, resulting in unchecked tumor 
progression.
Notch activity plays a leading role in cancer cell senescence, 
primarily through the isoforms, Notch1, Notch3, and the ligand 
Jagged1 (256, 257). Notch1 involvement has been studied 
extensively and therefore its role is better defined. Several reports 
associate Notch1 activity with the onset of senescence in cancer, 
but the temporal regulation is complicated by the sequence of 
two distinct phases, necessary for the full acquisition of senes-
cence, and differently regulated by Notch activity. In vitro and 
in  vivo experiments from Hoare et  al. (256) show that Notch1 
activity is dynamically upregulated during the first phase of 
induction in both oncogene-induced senescence (OIS) and DNA 
damage-induced senescence (DDIS) and returns to basal levels 
when senescence is completely established (Figure 6). These two 
FiGURe 6 | Notch signaling regulates cancer cell senescence and the 
associated secretome profile. Notch activity is dynamically regulated during 
the acquisition of the full cell senescence. Through an elegant work on 
cancer models of oncogene-induced senescence (OIS), Notch-induced 
senescence (NIS), and DNA damage senescence induced in human diploid 
fibroblasts, and confirmed in in vitro models of pancreatic and liver cancer, 
Hoare et al. demonstrated that the first phase of senescence is 
characterized by the activation of Notch with the consequent promotion  
of transforming growth factor-β (TGF-β) expression and the inhibition of 
transcriptional activity of C/EBPβ transcriptional activity. This is unleashed 
with Notch downregulation during full senescence acquisition resulting in  
the expression of pro-inflammatory senescence-associated secretory  
profile (SASP) (256). See text for details.
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phases, characterized, respectively, by high and low levels of 
Notch activity, also display two distinct secretomes: the first 
characterized by anti-inflammatory cytokines and the second 
by pro-inflammatory cytokines and matrix-modifying enzymes 
(i.e., MMP1, 3, 10). The mechanism underlying the switch 
between the two phases involves the interplay between Notch1 
and CCAAT/enhancer-binding protein β (C/EBPβ) (256), as 
depicted in Figure  6. In this first phase, high Notch signaling 
inhibits C/EBPβ transcriptional activity and promotes the secre-
tion of TGF-β. This cytokine mediates immunosuppression along 
with the growth arrest observed in senescence, in part through 
the induction of p15 and p21. Upon full senescence achievement, 
the decrease of Notch activity releases the transcriptional activity 
of C/EBPβ that, together with NF-κB, coordinates the secretion 
of pro-inflammatory SASP including IL-6, IL-8, and the master 
senescence regulator IL-1A (255).
While OIS and DDIS require a biphasic modulation of Notch 
signaling, tumor cells showing steady high Notch signaling levels 
are characterized by a different form of senescence, known as 
Notch-induced senescence (NIS). NIS produces an unusual 
immunosuppressive cytokine profile characterized by increased 
TGF-β, growth arrest, and inhibition of pro-inflammatory 
cytokines (69). Accordingly, Kagawa et al. (258) reported evidence 
that the ectopic expression of ICN1 induced cellular senescence 
by inhibiting cell proliferation, finally resulting in irreversible 
cell-cycle arrest in G0/G1 phase, through the increased expres-
sion of p16INK4A and p21 and Rb dephosphorylation. Similarly, 
Notch3 increased expression in replicative senescence and in 
DDIS was associated to increased p21 (257).
In addition, the lack of inflammatory secretome associated to 
NIS was shown to affect in vivo lymphocyte recruitment at the 
tumor site, at least in part by hampering lymphocyte adhesion to 
endothelial cells and preventing extravasation (256). This is impor-
tant, since the local infiltration of innate and adaptive immune 
system is key to the clearance of senescent cancer cells. Several 
evidences confirm that Notch signaling antagonizes the forma-
tion of an immune-stimulating microenvironment associated to 
senescence. Indeed, Kang et al. (259) recently reported that inhi-
bition of Notch activity, obtained through the use of DN-MAML, 
results in: (1) senescent phenotype with the release of immune-
stimulating cytokines and chemokines that favor the formation of 
an immunostimulatory microenvironment, including IL-8, IL-1α, 
IL-1β (260), IFN-γ, IFN-β, CCL2 (195), CCL5, CXCL9, CXCL10, 
and CXCL11, CCL18; (2) the tumor infiltration by immune cells, 
such as DCs, NKs, and CD8+ T cells, in in vivo syngeneic animal 
models.
Another important key feature regulated by Notch signaling 
is the transmission of senescence from the senescent cancer cells 
to the neighboring non-senescent ones, caused by two distinct 
mechanisms: secreted cytokines or cell–cell contact.
The first mechanism involves Notch1-driven TGF-β and 
induces senescence in a paracrine manner, at least in part by 
promoting of the expression of the cyclin-dependent-kinase 
inhibitors p15 and p21 in neighboring cells. The second mecha-
nism involves a cell–cell communication mediated by Notch 
signaling. Notch activation occurring during OIS or NIS results 
in increased Jagged1 expression. Jagged1 expressed by senescent 
cancer cells acts as a master mediator of senescence-lateral induc-
tion by activating Notch receptors expressed by neighboring 
cells (256).
The evidence that many of the Notch target genes encoding 
for cytokines, i.e., IL-1β, IL-6, IL-8, CCL2, and CCL5 (31, 33, 
173, 195), above reported in different tumor settings are negatively 
regulated by Notch during cancer cell senescence underlines that 
Notch signaling outcome is highly context dependent.
Senescence may be transmitted to nearby cancer cells, but also 
to the healthy cells of the surrounding TME. Indeed, Procopio 
et al. (261) recently uncovered the diffusion of senescence from 
cancer cells to CAFs through a different mechanism associated 
with reduced levels of the RBP-Jk transcription factor. RBP-Jk 
down-modulation is exhibited by CAFs derived from different 
tumors, including skin squamous cell carcinoma (262), head/
neck (263), breast (264), and lung (265) cancers, in comparison 
to normal fibroblasts. RBP-Jk knockdown in primary fibroblasts 
from dermis, oral mucosa, breast, and lung, induces cellular 
senescence, and increases the pro-inflammatory cytokines, such 
as IL-6. In this scenario, Notch role appears to be further compli-
cated by p53. RBP-Jk acts as a repressor for p53, with which shares 
DNA binding sites on regulative regions of senescence-associated 
target genes, including p21, and possibly inflammatory cytokines, 
such as IL-6. Low levels of RBP-Jk allow p53-mediated transcrip-
tion and, additionally, the repressor-like activity of RBP-Jk may 
be unleashed by Notch1 activation, also induced by nearby 
Jagged-bearing cells (261).
Although several facets remain to be elucidated, including 
the interplay of Notch activity with other signaling pathways 
involved in the regulation of senescence, Notch activity in cancer 
cell senescence is crucial in diffusing senescence from cancer 
cells to other malignant cells and to non-cancerous cells, and in 
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providing a senescence-associated anti-inflammatory secretome 
that contributes to hamper the antitumor immune response. 
Overall, the evidence indicates that a Notch-directed therapeutic 
approach is a unique opportunity to re-establish the local antitu-
mor response of the immune system.
CONClUSiON
Tumor cells are characterized by their ability to shape the sur-
rounding microenvironment, altering the behavior of neighboring 
normal cells to sustain tumor growth, drug resistance, neoangio-
genesis, and bone destruction. In addition, malignant cells cause 
an immune imbalance in the TME, impairing the functions of 
cells involved in innate and adaptive immune response, leading 
to immunesuppression, and promoting inflammation. Overall, 
these processes contribute to determine the fatal outcome of 
several malignancies.
In this context, increasing attention has recently been paid to 
the cytokine network in the TME and to its ability to redefine 
immune cells differentiation, as testified by increasing number of 
clinical trials involving drugs or monoclonal antibodies targeting 
cytokines or their receptors (see Table 2).
Here, we have provided a full overview about the pleiotropic 
role of Notch signaling dysregulation in tuning the expression 
and activity of a plethora of cytokines involved in the pathological 
interaction between tumor and TME.
This evidence together with the key role played by Notch dys-
regulation in several malignancies, suggests that a Notch-targeted 
approach may be sufficient to restore the physiological cytokine 
milieu, overcoming tumor-driven immune reprogramming, and 
improving patient’s overall survival.
Unfortunately, the majority of Notch-directed approaches 
are based on GSIs, whose “pan Notch”-blocking activity results 
in patient’s gastrointestinal toxicity due to intestine metaplasia 
(279, 280). Thus, a better dissection of the specific contribution 
of the different Notch ligands and receptors to the dysregulation 
of the cytokine milieu would help to better refine therapeutic 
strategies directed to restore the antitumor immune response, 
avoiding GSI-related side effects. At this purpose, recently a new 
generation of drugs has been developed such as monoclonal 
antibodies targeting Notch1 (281), Notch2/3 (282), Dll4 (283), 
or small molecules targeting Jagged1/2 (284, 285). These novel 
therapeutic strategies promise to specifically inhibit the dysregu-
lated members of the Notch pathway, contributing to restore the 
normal activity of the immune system, and finally hampering 
tumor progression.
aUTHOR CONTRibUTiONS
All the listed authors have provided a substantial, direct, and 
intellectual contribution to the work and approved it for the 
publication.
FUNDiNG
RC is supported by grants from the National Cancer Institute (NCI 
1R21CA194679-01); Associazione Italiana Ricerca sul Cancro to 
RC (IG 20614); Dept. of Health Sciences, Università degli Studi di 
Milano (Project Linea 2B, PSR2015-1717RCHIA_M CUP). MC 
is supported by Fondazione Italiana per la Ricerca sul Cancro 
(post-doctoral fellowship 18013); NP is supported by Università 
degli Studi di Milano (post-doctoral fellowship type A).
Table 2 | Overview of the last clinical trials that targets cancer-altered cytokines.
Cytokine Cancer type Clinical trial 
phase
Drug ClinicalTrials.gov 
identifier or referencea
TGFβ Prostate cancer Phase 2 Galunisertib NCT02452008
TGFβ Advanced metastatic carcinoma Phase 1 Galunisertib NCT02423343
TGFβ Hepatocellular carcinoma Phase 2 Galunisertib NCT01246986 (266)
TGFβ Metastatic cancer, pancreatic cancer Phase 1/2 Galunisertib NCT01373164 (267)
IL-6 Patients with hormone refractory prostate cancer Phase 2 CNTO 328 (anti IL-6 monoclonal antibody) alone or in 
combination with n combination with mitoxantrone
NCT00433446, 
NCT00385827 (268)
IL-6 Patients with unresectable or metastatic kidney cancer Phase 2 Siltuximab (CNTO 328, anti IL-6 monoclonal antibody) NCT00311545
IL-6R Subjects with metastatic HER2 positive breast cancer Phase 1 Anti-IL-6R monoclonal antibody tocilizumab in 
combination with trastuzumab and pertuzumab in
NCT03135171 (269)
IL-6 Subjects with relapsed or refractory multiple myeloma Phase 2 CNTO 328 (anti-IL-6 monoclonal antibody) in 
combination with bortezomib
NCT00401843 (270)
IL-6 Subjects with newly diagnosed, previously untreated 
multiple myeloma requiring systemic chemotherapy
Phase 1b/2 Siltuximab (CNTO 328) with lenalidomide, bortezomib, 
dexamethasone
NCT01531998 (271)
CXCR4 Acute myeloid leukemia Phase 1/2 Plerixafor NCT01435343 (272)
CXCR4 Refractory acute lymphoblastic leukemia Phase 1 Plerixaflor NCT01319864 (273)
RANKL Breast cancer Early phase 1 Denosumab NCT02900469
RANKL Bone metastases Phase 1 JMT103 NCT03550508
TNF1α Advanced cancer Infliximab (274)a
IL-17 Patients with relapsed and/or refractory multiple 
myeloma
Phase 1/1b CJM112/anti-IL-17A antibody alone or in combination 
with drug: PDR001, anti-PD1 antibody
NCT03111992 (recruiting)
CCL2 Solid tumors Phase 1 Carlumab NCT01204996 (275)
CCL2 Prostate cancer Phase 2 Carlumab NCT00992186 (276)
VEGF Many cancer types Phase 1/2/3 Bevacizumab and others anti-VEGF drugs (277, 278)
aDue to the very high number of clinical trials targeting these cytokines, here we referred to review papers that provide an overview of the different experimentations.
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